Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 404-310-0 | CAS number: 10591-85-2 PERKACIT TBZTD; PERKACIT TBZTD PDR; PERKACIT TBZTD PDR-D; TBZD
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
No adverse effect was observed in the oral 28 -day repeated toxicituy study performed with TBzTD up to 1000 mg/kg/day.
Key value for chemical safety assessment
- Toxic effect type:
- dose-dependent
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- 1981
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Route of administration:
- oral: gavage
- Vehicle:
- propylene glycol
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Samples of formulations prepared during weeks 1, 2, 3 and 4 were analysed to check the accuracy of preparation.
Concentration of the test article in vehicle was determined weekly on days 6, 13, 20 and 27.
TBzTD was determined to be stable for at least 4 hours in propylene glycol at all concentrations tested. TBzTD formed a homogeneous suspension in propylene gl ycol at all concentrations tested. - Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- daily
- Dose / conc.:
- 50 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 200 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent vehicle
- Positive control:
- no
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
DETAILED CLINICAL OBSERVATIONS: Yes
BODY WEIGHT: Yes
FOOD CONSUMPTION Yes
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
CLINICAL CHEMISTRY: Yes
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes - Statistics:
- yes
- Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- One male of the control and one female receiving 200 mg/kg/day showed slight diarrhoea on days 8 and 2, respectively.
No clinical signs were noted in treated males and in females receiving 50 or 1000 mg/kg/day.
One control male showed a broken left upper incisor on day 12 and a broken right upper incisor on day 14. One male receiving 50 mg/kg/day showed a broken left upper incisor on day 12. - Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- One female died on day 11 of dosing. This early death was in the absence of any signs of toxicity, not considered to be treatment related.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Body weight and body weight gain of treated animals remained similar to those of control rats over the study period.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- There were no differences in appetite between treated and control animals during the 29 day observation period.
- Description (incidence and severity):
- n/a
- Description (incidence and severity):
- n/a
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Changes in red blood cell parameters between treated and control animals, included a statistically significant increase in red blood cell counts and hemoglobin in females receiving 1000 mg/kg/day and a statistically significant decrease in red cell distribution width in females receiving 50, 200 or 1000 mg/kg/day.
However, these values were within the range normally seen in rats of this age and strain and therefore not considered to be of toxicological significance.
Total white blood cell counts achieved a level of statistical significance in their difference from controls for females receiving 50 or 200 mg/kg/day, but in the absence of any corresponding effect in females receiving 1000 mg/kg/day and in treated males, these increases were considered to have arisen by chance and to be of no biological significance.
Eosinophils were noted as statistically significant high in comparison with control levels for females receiving 1000 mg/kg/day. However, of the 4 values measured, only 2 values fell outside the normal expected range. Therefore, in the absence of consistent response, a treatment related distribution or similar response in males this finding is considered to be the result of extreme biological variation and not directly related to the treatment.
Other differential white blood cell counts did not differ significantly from control values. - Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no toxicologically significant differences in blood chemistry parameters between control and treated animals of both sexes.
Statistically significant differences arising between Calcium of males receiving 50 mg/kg/day, Sodium of males receiving 200 mg/kg/day, GOT of females receiving 1000 mg/kg/day and Albumin of females receiving 200 or 1000 mg/kg/day in comparison with controls were within biologically normal limits and considered to have occurred fortuitously. - Endocrine findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Spleen weights of treated females were slightly, but statistically significantly decreased in comparison with control weights. However, after correction for body weight, these decreases attained a level of statistical significance only for females receiving 200 mg/kg/day.
However, all values were within the range normally seen for rats of this age and strain. - Gross pathological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Pelvic dilatation of the kidneys was noted in 2 females receiving 50 mg/kg/day. This finding is known to occur spontaneously in rats of this age and strain and not considered of toxicological significance.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- A small number of microscopic findings were noted in the rats examined. These microscopic findings did not distinguish treated rats from controls and were findings commonly noted in rats of this age and strain.
- Histopathological findings: neoplastic:
- not examined
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Critical effects observed:
- no
- Conclusions:
- No treatment-related changes were noted in any dose group up to 1000 mg/kg bw per day. From the results presented in this study a no effect level (NOEL) was established at 1000 mg/kg/day.
- Executive summary:
The sub-acute toxicity of tetrakis(phenylmethyl)thioperoxydi(carbothioamide) (TBzTD) was investgated according to OECD 407: Repeated Dose 28-day Oral Toxicity Study in Rodents.
TBzTD was administered daily by gavage to SPF-bred Sprague-Dawley rats. The study comprised of four group of 5 male and 5 female rats : 0, 50, 200 and 1000 mg/kg/day.
No treatment-related changes (mortalility, clinical sign, bodyweight, food consumption, hematology, biochemistry, organ weight, macroscopic and microscopic examinations) were noted in any dose group.
Based on the results, a no effect level (NOEL) was established at 1000 mg/kg/day.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- The study is considered as reliable.
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
28 -day repeated toxicity study
The sub-acute toxicity of tetrakis(phenylmethyl)thioperoxydi(carbothioamide) (TBzTD) was investgated according to OECD 407: Repeated Dose 28-day Oral Toxicity Study in Rodents.
TBzTD was administered daily by gavage to SPF-bred Sprague-Dawley rats. The study comprised of four group of 5 male and 5 female rats : 0, 50, 200 and 1000 mg/kg/day.
No treatment-related changes (mortality, clinical sign, bodyweight, food consumption, hematology, biochemistry, organ weight, macroscopic and microscopic examinations) were noted in any dose group.
Based on the results, a no effect level (NOEL) was established at 1000 mg/kg/day.
Justification for classification or non-classification
Based on the available data, no classification for repeated toxicity is required for TBzTD according to the Regulation EC n°1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.